NCT07839858Completed
A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera: A Multicenter, Retrospective, Non-interventional Study in France
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
The aim of this study was to assess which cytoreductive treatments are currently administered in standard practice as second-line therapy to patients with polycythemia vera (PV) in France and to find out the reasons physicians switch treatments. In addition, the research aimed to describe real-world effectiveness of second-line cytoreductive therapies and the occurrence of adverse events of special interest. Study data were collected from the medical charts of patients who initiated a second-line cytoreductive agent for the treatment of PV and received their first dose between 1 Jan 2022 and 31 Dec 2023.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 237 (actual)
- First submitted
- 18 Sept 2026
- Start date
- 13 Mar 2025
- Primary completion date
- 14 Oct 2025
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT07839858
What you commit to
- Study type: Observational
- Participants enrolled: 237
- From 13 Mar 2025 to the primary completion date, 14 Oct 2025
- 48 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who died before study initiation and who had opposed to data use for research purpose prior to their death.
Other
- Patient alive at study initiation who opposed to data use for research purposes.
- Patient who took part in an interventional clinical trial(s) between 01 January 2022 and 31 December 2023.
Who the study is looking for
- Male or female patient diagnosed with PV after 01 Jan 2014 according to World Health Organization (WHO) criteria.
- Patient ≥ 18 years of age at the time of PV diagnosis.
- Patient who received a first dose of a second-line cytoreductive treatment between 01 Jan 2022 and 31 Dec 2023.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (48)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.